GlassScriptPhysician profile
Ambika P Ashraf
NPI 1134232226
$39,401.48
in general payments reported to CMS, 2019-2025
21 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $57.57 · 2021: $2,201 · 2022: $285 · 2023: $7,352 · 2024: $13K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Consulting Fee: $12K · Travel and Lodging: $4,234 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900 · Food and Beverage: $1,621 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,365.00 |
| Consulting Fee | $12,478.00 |
| Travel and Lodging | $4,233.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
| Food and Beverage | $1,621.03 |
| Education | $110.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $15,418.84 | 2024-2025 | Juxtapid, Myalept |
| Genzyme Corporation | $10,273.37 | 2022-2025 | |
| Biomarin Pharmaceutical INC. | $9,197.94 | 2020-2023 | Voxzogo 1.2mg |
| Regeneron Pharmaceuticals, INC. | $2,860.00 | 2025 | Evkeeza |
| Novo Nordisk INC | $248.63 | 2020-2024 | Sogroya |
| Beta Bionics, INC. | $226.04 | 2023-2024 | Ilet Bionic Pancreas |
| Sanofi-Aventis U.S. LLC | $149.08 | 2025 | |
| Kyowa Kirin, INC. | $125.96 | 2024 | Crysvita |
| Rigel Pharmaceuticals, INC. | $124.85 | 2021 | |
| Tandem Diabetes Care, INC. | $116.86 | 2022 | |
| Tolmar, INC. | $114.47 | 2024 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Abbott Laboratories | $87.23 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $72.94 | 2025 | |
| Amryt Pharma Holdings LTD | $64.52 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $64.15 | 2024 | |
| Medtronic, INC. | $57.05 | 2023-2024 | Minimed 780g |
| Ferring Pharmaceuticals INC. | $47.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $35.89 | 2021-2023 | Evkeeza |
| Genentech USA, INC. | $15.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambika Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.